These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30472908)

  • 1. Risk factors for cytomegalovirus disease with cytomegalovirus re-activation in patients with rheumatic disease.
    Kaneshita S; Kida T; Yokota I; Nagahara H; Seno T; Wada M; Kohno M; Kawahito Y
    Mod Rheumatol; 2020 Jan; 30(1):109-115. PubMed ID: 30472908
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical significance of cytomegalovirus (CMV) pp65 antigenemia in the prediction of CMV infection during immunosuppressive therapy for rheumatic disease.
    Suga K; Nishiwaki A; Nakamura T; Kagami SI
    Rheumatol Int; 2023 Jun; 43(6):1093-1099. PubMed ID: 36042051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of cytomegalovirus (CMV)-pp65 antigenemia in the diagnosis of CMV disease in human immunodeficiency virus-infected patients.
    Reynes J; Montes B; Atoui N; Segondy M
    J Med Virol; 1996 Jul; 49(3):195-8. PubMed ID: 8818964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of cytomegalovirus quantification in blood by the R-gene real-time PCR test].
    Marque-Juillet S; Touzard A; Monnier S; Fernand-Laurent C; Therby A; Rigaudeau S; Harzic M
    Pathol Biol (Paris); 2010 Apr; 58(2):162-5. PubMed ID: 19854587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevation of cytomegalovirus antigenemia predicts serious infection and death in patients receiving immunosuppressive therapies for autoimmune diseases.
    Yoshihara R; Komai T; Shoda H; Fujio K
    Int J Rheum Dis; 2020 Nov; 23(11):1534-1540. PubMed ID: 33051990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus (CMV) DNA amplification from plasma compared with CMV pp65 antigen (ppUL83) detection in leukocytes for early diagnosis of symptomatic CMV infection in kidney transplant patients.
    Wirgart BZ; Claesson K; Eriksson BM; Brundin M; Tufveson G; Tötterman T; Grillner L
    Clin Diagn Virol; 1996 Nov; 7(2):99-110. PubMed ID: 9137866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia.
    Sénéchal M; Dorent R; du Montcel ST; Fillet AM; Ghossoub JJ; Dubois M; Pavie A; Gandjbakhch I
    Clin Transplant; 2003 Oct; 17(5):423-7. PubMed ID: 14703924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
    Capria S; Gentile G; Capobianchi A; Cardarelli L; Gianfelici V; Trisolini SM; Foà R; Martino P; Meloni G
    J Med Virol; 2010 Jul; 82(7):1201-7. PubMed ID: 20513085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of latent cytomegalovirus infection in patients with rheumatologic disease: a case-control study.
    Gardiner BJ; Haas EM; Bailey RC; Chow JK; Snydman DR
    Rheumatol Int; 2019 Jul; 39(7):1229-1240. PubMed ID: 31076831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose corticosteroid therapy for collagen vascular diseases.
    Yamashita M; Ishii T; Iwama N; Takahashi H
    Clin Exp Rheumatol; 2006; 24(6):649-55. PubMed ID: 17207380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with cytomegalovirus antigenemia in patients with rheumatic disease: A retrospective study.
    Ogata H; Aoki N; Nagano K; Hakamata M; Bamba Y; Shibata S; Koizumi T; Ohshima Y; Watanabe S; Moro H; Koya T; Kikuchi T
    J Infect Chemother; 2022 Nov; 28(11):1471-1477. PubMed ID: 35850402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection.
    Mengoli C; Cusinato R; Biasolo MA; Cesaro S; Parolin C; Palù G
    J Med Virol; 2004 Sep; 74(1):78-84. PubMed ID: 15258972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment.
    Allice T; Cerutti F; Pittaluga F; Varetto S; Franchello A; Salizzoni M; Ghisetti V
    J Virol Methods; 2008 Mar; 148(1-2):9-16. PubMed ID: 18045702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H; Eljed H; Greco A; Lakhal A; Torjman L; Abdelkefi A; Ben Othmen T; Ladeb S; Slim A; Zouari B; Abdeladhim A; Ben Hassen A
    Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus load in whole blood is more reliable for predicting and assessing CMV disease than pp65 antigenaemia.
    Hardie DR; Korsman SN; Hsiao NY
    J Virol Methods; 2013 Oct; 193(1):166-8. PubMed ID: 23792685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation.
    Nakamura R; Cortez K; Solomon S; Battiwalla M; Gill VJ; Hensel N; Childs R; Barrett AJ
    Bone Marrow Transplant; 2002 Aug; 30(4):235-42. PubMed ID: 12203140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.